Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-05-02
2006-05-02
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S210010
Reexamination Certificate
active
07037944
ABSTRACT:
The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
REFERENCES:
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 0576357 (1993-12-01), None
patent: 0656354 (1995-06-01), None
patent: 0658548 (1995-06-01), None
patent: WO 90/08110 (1990-06-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 97/19063 (1997-05-01), None
patent: WO 98/18481 (1998-05-01), None
patent: WO 98/32441 (1998-07-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 01/15609 (2000-03-01), None
patent: WO 00/46209 (2000-08-01), None
patent: WO 01/64634 (2001-09-01), None
D. H. Ryan, et al, Sibutramine: A Novel New Agent for Obesity Treatment, Obesity Research (1995, pp. 559S-559S, vol. 3).
Fanghanel G., et al, A Clinical Trial of the Use of Sibutramine for the Treatment of Patients Suffering Essential Obesity, International Journal Of Obesity (2000, pp. 144-150, vol. 24).
G. A. Bray, et al, Sibutramine Produces Dose-Related Weight Loss, Obesity Research (1999, pp. 189-198, vol. 7).
G. Colombo, et al, Appetite Suppression and Weight Loss After the Cannabinoid Antagonist SR, 141716 Life Sciences (1998, pp. 113-117, vol. 63).
H. C. Jackson, et al, Comparison of the Effects of Sibutramine and Other Monoamine Reuptake Inhibitors on Food intake in the Rat, British Journal of Pharmacology (1997, pp. 1758-1762, vol. 121).
J. Simiand, et al, SR 141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoeet Behavioral Pharmacology (1998, pp. 179-181, vol. 9).
Jules Hirsch, Magic Bullet For Obesity, BMJ (1998, pp. 1136-1138, vol. 317).
M. Nakazi et al., Inhibition of Serotonin Release in the Mouse Brain Via Presynaptic Cannabinoid CB1 Receptors, Naunyn-Schmiedeberg's Arch Pharmacol (2000, pp. 19-24, vol. 361).
Petitet François
Picaut Philippe
Piot-Grosjean Odile
Aventis Pharma S.A.
Spivack Phyllis G.
Strupczewski Joseph
LandOfFree
Combination of a CB1 receptor antagonist and of sibutramine,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of a CB1 receptor antagonist and of sibutramine,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of a CB1 receptor antagonist and of sibutramine,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543432